Another EpiPen Is Now on the Market
Teva Pharmaceuticals has finally launched its generic version of Mylanâs EpiPen. The Petah, Tikvah, Israel-based companyâs emergency allergy shot will be priced at $300 â the same as Mylanâs generic. Teva received approval for its version of EpiPen in August.
The generic will be available in limited supply and the company will launch a lower-dose - the EpiPen Jr. sometime next year, the company said.
âWeâre pleased to provide access to Epinephrine Injection (Auto-Injector) for patients who may experience life-threatening allergic emergencies and weâre fully dedicated toward ensuring additional supply in 2019,â Brendan OâGrady, EVP and Head of North America Commercial at Teva Pharmaceutical, said in a release.
Epinephrine Injection (Auto-Injector) is a prescription medicine in a disposable, pre-filled automatic injection device (auto-injector) used to treat life-threatening, allergic emergencies including anaphylaxis in people who are at risk for or have a history of serious allergic emergencies. Each device contains a single dose of epinephrine.
Why this News is Significant
Teva launching its generic takes some of the pressure off since Mylanâs product had a shortage earlier this year.
Back in May, Mylan said it had alerted FDA that there could be trouble in getting the EpiPen prescript...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Canada Health | Emergency Medicine | Israel Health | Middle East Health | Pfizer | UK Health